Natera (NASDAQ:NTRA) Price Target Raised to $175.00 at TD Cowen

Natera (NASDAQ:NTRA) had its price objective lifted by TD Cowen from $155.00 to $175.00 in a report published on Wednesday morning,Benzinga reports. TD Cowen currently has a buy rating on the medical research company’s stock.

Other research analysts have also issued reports about the stock. Robert W. Baird lifted their price target on shares of Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a report on Wednesday. UBS Group lowered their target price on Natera from $160.00 to $145.00 and set a “buy” rating for the company in a report on Friday, August 9th. Stephens reissued an “overweight” rating and issued a $125.00 price target on shares of Natera in a report on Friday, August 9th. BTIG Research upped their price objective on Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Finally, Leerink Partners increased their target price on Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. One investment analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, Natera currently has an average rating of “Moderate Buy” and a consensus price target of $137.65.

Natera Trading Down 3.3 %

Shares of NASDAQ NTRA opened at $146.06 on Wednesday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.01 and a current ratio of 4.39. The stock’s 50 day moving average price is $127.38 and its two-hundred day moving average price is $115.61. Natera has a 52-week low of $52.01 and a 52-week high of $167.79.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. During the same period in the prior year, the company posted ($0.95) EPS. The business’s revenue was up 63.9% compared to the same quarter last year. As a group, equities research analysts predict that Natera will post -1.7 earnings per share for the current fiscal year.

Insider Activity

In other Natera news, insider Solomon Moshkevich sold 1,196 shares of the company’s stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $118.21, for a total value of $141,379.16. Following the transaction, the insider now owns 110,695 shares in the company, valued at approximately $13,085,255.95. This represents a 1.07 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Steven Leonard Chapman sold 5,024 shares of Natera stock in a transaction on Monday, September 16th. The shares were sold at an average price of $128.48, for a total transaction of $645,483.52. Following the sale, the chief executive officer now directly owns 195,686 shares of the company’s stock, valued at $25,141,737.28. This trade represents a 2.50 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 36,821 shares of company stock worth $4,776,878 in the last 90 days. Company insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Covestor Ltd lifted its holdings in shares of Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after buying an additional 95 shares during the last quarter. GAMMA Investing LLC lifted its stake in Natera by 32.7% in the third quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after acquiring an additional 106 shares during the last quarter. CIBC Asset Management Inc lifted its stake in Natera by 3.3% in the third quarter. CIBC Asset Management Inc now owns 3,477 shares of the medical research company’s stock valued at $441,000 after acquiring an additional 111 shares during the last quarter. RiverPark Advisors LLC grew its position in Natera by 3.5% in the third quarter. RiverPark Advisors LLC now owns 3,347 shares of the medical research company’s stock worth $425,000 after acquiring an additional 112 shares in the last quarter. Finally, Moss Adams Wealth Advisors LLC increased its stake in shares of Natera by 5.4% during the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 2,646 shares of the medical research company’s stock worth $336,000 after purchasing an additional 135 shares during the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.